Maccura Biotechnology obtains registration for new diagnostic kit
Maccura Biotechnology announced that it has received a product registration certificate from the National Medical Products Administration for its "Abnormal Prothrombin Precursor Assay Kit (Direct Chemiluminescence Method)". The kit is designed for in vitro quantitative determination of abnormal prothrombin precursor levels in human serum or plasma. It uses a double-antibody sandwich method and is intended for monitoring liver cancer progression or treatment effectiveness. Maccura believes that this new product, a chemiluminescence reagent kit, will enrich the company's product offerings, enhancing its market competitiveness. While the company anticipates a positive impact on market expansion and future operations, the actual sales performance will depend on future market promotion, with no guarantees about future revenue. Investors are advised to be aware of investment risks. The announcement was made on March 31, 2025.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Maccura Biotechnology publishes news
Free account required • Unsubscribe anytime